Egalet Corp. of Pennsylvania recently obtained a complete response letter from the U.S. Food and Drug Administration about its Oxaydo tablets in 10 mg and 15 mg dosage strengths. Read More »
DelMar Pharmaceuticals recently presented a poster on dianhydrogalactitol at the Society for Neuro-Oncology's 4th Pediatric Neuro-Oncology Basic and Translational Research Conference, which took place at the Wyndham New Yorker Hotel in New York City in June. Read More »
Pfizer Inc. recently published noninferiority results from its study of Xeljanz, a twice-daily monotherapy to be used in combination with methotrexate in treating patients with moderate to severe rheumatoid arthritis. Read More »
Janssen Biotech's Darzalex immunotherapy was approved by the U.S. Food and Drug Administration for treating patients with multiple myeloma in combination with pomalidomide and dexamethasone. Read More »
Lexicon Pharmaceuticals Inc. recently presented its two sotagliflozin studies, inTandem1 and inTandem2, at the 77th American Diabetes Association Scientific Sessions in San Diego, California. Read More »
CSL Behring's Haegarda drug, the only subcutaneous therapy for preventing hereditary angioedema attacks in both adolescents and adults, was approved by the U.S. Food and Drug Administration. Read More »
Ipsen Biopharmaceuticals Inc., an affiliate of Ipsen SA, has had its Dysport injection for treating spasticity in adults approved for expanded use by the U.S. Food and Drug Administration. Read More »
Sandoz's Abbreviated New Drug Application for fluticasone propionate/salmeterol combination product, a substitutable generic version of Advair Diskus, was accepted by the U.S. Food and Drug Administration. Read More »
Amgen recently announced that its Mimpara drug has been given a positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »
AbbVie's chronic hepatitis C virus infection drug, Maviret, was granted a positive opinion by the European Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »
Halozyme Therapeutics Inc.'s Genentech’s Rituxan Hycelatm, which uses Halozyme’s hyaluronidase human enhance technology, was approved by the U.S. Food and Drug Administration for subcutaneous injection in multiple blood cancer indications. Read More »
Lannett Company Inc. now has access to “the lion's share of the market” for newly approved dosage strengths of its hydrocodone bitartrate and acetaminophen tablets following recent FDA authorization, according to Lannett CEO Arthur Bedrosian. Read More »
The rights to vaccine technologies designed to combat measles and pertussis will be transferred to an India-based business following a pair of recent licensing agreements to hasten affordable protection in India, China and additional nations. Read More »
Introducing an innovative “bi-directional integration” between two existing systems, Baxter International Inc. recently combined its DoseEdge pharmacy workflow management system with the Epic Willow Inpatient Pharmacy System. Read More »
A prescription chemotherapy drug manufactured by Florida-based Breckenridge Pharmaceutical Inc. has earned Food and Drug Administration approval, moving a step closer to combating a rare type of blood and bone marrow cancer. Read More »
Intraocular therapeutics manufacturer Icon Bioscience Inc., focusing on innovative eye care, recently obtained U.S. Food and Drug Administration acceptance of its new drug application for Dexycu, with full approval anticipated in 2018. Read More »
To combat severe pain for which alternative treatments fall short, BioDelivery Sciences International Inc.’s Belbuca (buprenorphine hydrochloride buccal film) product has just gained approval from Canada’s regulatory body, Health Canada, earning its Notice of Compliance. Read More »
"Drug manufacturers, wholesalers, pharmacies, and insurance companies are just some of the entities that should be involved in finding a true market solution" to drug pricing," writes Dr. Kathleen Iacocca, professor at Villanova University School of Business. "The industry has to change itself to avoid Washington interference and all of those impacted need to be equally involved." Read More »
PharmaMar has obtained a trademark for its commercial formulation of PM 1183 (lurbinectedin) — developed for the treatment of ovarian and lung cancers — from European and U.S. authorities, the company announced recently from Madrid, Spain headquarters. Read More »
Adapt Pharma recently acknowledged the U.S. Drug Enforcement Administration's new guidance rules for first responders related to the hazards of fentanyl exposure. Read More »
Alerts Sign-up
